QQ客服 官方微博 反馈留言

浏览/检索结果: 共9条，第1-9条 帮助 限定条件 专题：西安交通大学    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303. 期刊论文 Thoracic cancer, 2019, 卷号: 10, 页码: 551-556 作者:  Si Xiaoyan;  Zhang Li;  Wang Hanping;  Zhang Xiaotong;  Wang Mengzhao 收藏  |  浏览/下载：34/0  |  提交时间：2019/11/19 non-small cell lung cancer  multi-target tyrosine kinase inhibitor  Adverse event  anlotinib   Dose modification and therapy interruption due to adverse events in treatment with anlotinib for refractory advanced NSCLC: Data from ALTER0303 会议论文 作者:  Zhang, L.;  Si, X.;  Wang, H.;  Zhang, X.;  Wang, M. 收藏  |  浏览/下载：6/0  |  提交时间：2019/11/19 Management of Anlotinib-Related Adverse Events: Data From ALTER 0303 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2018, 卷号: 13, 页码: S505-S506 作者:  Si, X.;  Zhang, L.;  Wang, H.;  Zhang, X.;  Wang, M. 收藏  |  浏览/下载：4/0  |  提交时间：2019/11/26 non-small cell lung cancer  Anlotinib  adverse event   The Impact of Anlotinib on Quality of Life in Patients with Advance NSCLC: Post-Hoc Analysis of a Phase III Randomized Control Trial (ALTER0303) 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2018, 卷号: 13, 页码: S505-S505 作者:  Si, X.;  Zhang, L.;  Wang, H.;  Zhang, X.;  Wang, M. 收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26 non-small cell lung cancer  quality of life  Anlotinib   Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. 期刊论文 JAMA oncology, 2018, 卷号: 4, 页码: 1569-1575 作者:  Han Baohui;  Li Kai;  Wang Qiming;  Zhang Li;  Shi Jianhua 收藏  |  浏览/下载：5/0  |  提交时间：2019/11/26 Prognostic factors of refractory NSCLC patients receiving anlotinib hydrochloride as the third- or further-line treatment 期刊论文 CANCER BIOLOGY & MEDICINE, 2018, 卷号: 15, 页码: 443-451 作者:  Wang, Jing;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li;  Shi, Jianhua 收藏  |  浏览/下载：5/0  |  提交时间：2019/11/26 Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer 期刊论文 LUNG CANCER, 2018, 卷号: 122, 页码: 32-37 作者:  Si, Xiaoyan;  Zhang, Li;  Wang, Hanping;  Zhang, Xiaotong;  Wang, Mengzhao 收藏  |  浏览/下载：3/0  |  提交时间：2019/11/26 Quality of life  Non-small cell lung cancer  Anlotinib   A Randomized Phase III Clinical Trial of Anlotinib Hydrochloride in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) 期刊论文 JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 页码: S886-S887 作者:  Han, Baohui;  Li, Kai;  Zhao, Yizhuo;  Wang, Qiming;  Zhang, Li 收藏  |  浏览/下载：9/0  |  提交时间：2019/11/26 NSCLC  multi-targeted tyrosine kinase inhibitor  Anlotinib   Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind, placebo-controlled phase 3 study 期刊论文 LANCET ONCOLOGY, 2017, 卷号: 18, 页码: S3-S3 作者:  Han, Baohui;  Li, Kai;  Wang, Qiming;  Zhao, Yizhuo;  Zhang, Li 收藏  |  浏览/下载：10/0  |  提交时间：2019/11/26